Adicet bio, inc. announces closing of $100 million public follow-on offering and exercise in full of the underwriters' option to purchase additional shares

Menlo park, calif. and boston, dec. 10, 2021 (globe newswire) -- adicet bio, inc. (“adicet”) (nasdaq: acet), a biotechnology company discovering and developing allogeneic gamma delta car t cell therapies for cancer and other diseases, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 937,500 shares of common stock, at a public offering price of $14.00 per share, less underwriting discounts and commissions. the aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $100.6 million. all of the shares in the offering are were sold by adicet.
ACET Ratings Summary
ACET Quant Ranking